1 Presented by Jeffrey Crawford, MD, Chief, Division of Medical Oncology, Professor of Medicine, Duke Cancer Institute, Durham, North Carolina, and George M. Rodgers, MD, PhD, Professor of Medicine, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.
Myeloid growth factors can reduce the risk of chemotherapy-induced neutropenia (CIN) and thus impact the survival of patients with cancer. Patients should be assessed for risk, taking into consideration patient-related risk factors and chemotherapy regimens. Patients stratified as having at least a 20% risk for CIN should be considered for prophylactic growth factors. The NCCN Guidelines for Myeloid Growth Factors provide category 1 recommendations for the daily use of filgrastim, tbo-filgrastim, and pegfilgrastim. Cancer-related anemia can be treated with erythropoiesis-stimulating agents, red blood cell transfusion, or intravenous iron.
Correspondence: Jeffrey Crawford, MD, Duke Cancer Institute, Duke University Medical Center, 441 Seeley G. Mudd Building, 10 Bryan Searle Drive, Box 3476, Durham, NC 27710. E-mail: firstname.lastname@example.orgCorrespondence: George M. Rodgers, MD, PhD, Huntsman Cancer Institute at the University of Utah, Division of Hematology, University of Utah Medical Center, 30 North 1900 East, Rm 5C-402, Salt Lake City, UT 84132. E-mail: email@example.com